-
Type
All -
Tags
All -
Strategic pillar
All -
Beamlines
All -
From Year
2020 -
To Year
All -
Quarter
All- All
- 2026 - Q4
- 2026 - Q3
- 2026 - Q2
- 2026 - Q1
- 2025 - Q4
- 2025 - Q3
- 2025 - Q2
- 2025 - Q1
- 2024 - Q4
- 2024 - Q3
- 2024 - Q2
- 2024 - Q1
- 2023 - Q4
- 2023 - Q3
- 2023 - Q2
- 2023 - Q1
- 2022 - Q4
- 2022 - Q3
- 2022 - Q2
- 2022 - Q1
- 2021 - Q4
- 2021 - Q3
- 2021 - Q2
- 2021 - Q1
- 2020 - Q4
- 2020 - Q3
- 2020 - Q2
- 2020 - Q1
- 2019 - Q4
- 2019 - Q3
- 2019 - Q2
- 2019 - Q1
- 2018 - Q4
- 2018 - Q3
- 2018 - Q2
- 2018 - Q1
- 2017 - Q4
- 2017 - Q3
- 2017 - Q2
- 2017 - Q1
- 2016 - Q4
- 2016 - Q3
- 2016 - Q2
- 2016 - Q1
- 2015 - Q4
- 2015 - Q3
- 2015 - Q2
- 2015 - Q1
- 2014 - Q4
- 2014 - Q3
- 2014 - Q2
- 2014 - Q1
- 2013 - Q4
- 2013 - Q3
- 2013 - Q2
- 2013 - Q1
- 2012 - Q4
- 2012 - Q3
- 2012 - Q2
- 2012 - Q1
- 2011 - Q4
- 2011 - Q3
- 2011 - Q2
- 2011 - Q1
- 2010 - Q4
- 2010 - Q3
- 2010 - Q2
- 2010 - Q1
- 2009 - Q4
- 2009 - Q3
- 2009 - Q2
- 2009 - Q1
- 2008 - Q4
- 2008 - Q3
- 2008 - Q2
- 2008 - Q1
- 2007 - Q4
- 2007 - Q3
- 2007 - Q2
- 2007 - Q1
- 2006 - Q4
- 2006 - Q3
- 2006 - Q2
- 2006 - Q1
- 2005 - Q4
- 2005 - Q3
- 2005 - Q2
- 2005 - Q1
- 2004 - Q4
- 2004 - Q3
- 2004 - Q2
- 2004 - Q1
- 2003 - Q4
- 2003 - Q3
- 2003 - Q2
- 2003 - Q1
- 2002 - Q4
- 2002 - Q3
- 2002 - Q2
- 2002 - Q1
- 2001 - Q4
- 2001 - Q3
- 2001 - Q2
- 2001 - Q1
| Publication | Beamlines | Type | Strategic Pillar |
|---|---|---|---|
| van Vliet, Vera J. E.; Huynh, Nhan; PalĂ , Judith; Patel, Ankoor; Singer, Alex et al. (2022). Ubiquitin variants potently inhibit SARS-CoV-2 PLpro and viral replication via a novel site distal to the protease active site. PLoS Pathogens 18(12) , e1011065. 10.1371/journal.ppat.1011065. | CMCF | Peer-Reviewed Article | Health |
| Vara, Brandon A.; Lim, Jongwon; Moure, Casey J.; Schneider, Sebastian E.; Yeung, Charles S. et al. (2026). Discovery and In Vivo Evaluation of Aryl Ether YAP1/TEAD Inhibitors for the Treatment of Hippo-Driven Malignancies. Journal of Medicinal Chemistry 69(4) , 4303-4316. 10.1021/acs.jmedchem.5c02997. [PDB: 9yk2] | CMCF-BM | Peer-Reviewed Article | Health |
| Varkaris, Andreas; Pazolli, Ermira; Gunaydin, Hakan; Wang, Qi; Pierce, Levi et al. (2023). Discovery and clinical proof-of-concept of RLY-2608, a first-in-class mutant-selective allosteric PI3Ka inhibitor that decouples anti-tumor activity from hyperinsulinemia. Cancer Discovery . 10.1158/2159-8290.cd-23-0944. [PDB: 8ts7] | CMCF-ID | Peer-Reviewed Article | Health |